Antibody-Based Formats to Target Glioblastoma: Overcoming Barriers to Protein Drug Delivery-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Antibody-Based Formats to Target Glioblastoma: Overcoming Barriers to Protein Drug Delivery

Published:2022-04-19 Issue:5 Volume:19 Page:1233-1247
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Ghosh Saikat¹^ORCID,Huda Pie¹,Fletcher Nicholas L.¹^ORCID,Howard Christopher B.¹^ORCID,Walsh Bradley²,Campbell Douglas²,Pinkham Mark B.³,Thurecht Kristofer J.¹^ORCID

Affiliation:

1. Centre for Advanced Imaging (CAI), Australian Institute for Bioengineering and Nanotechnology (AIBN) and ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland, Brisbane, Queensland 4072, Australia

2. GlyTherix, Ltd., Sydney, New South Wales 2113, Australia

3. Department of Radiation Oncology, Princess Alexandra Hospital, Woolloongabba, Queensland 4102, Australia

Funder

National Health and Medical Research Council

Australian Research Council

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.1c00996

Reference153 articles.

2. Glial Cells and Their Function in the Adult Brain: A Journey through the History of Their Ablation

3. Glioblastoma-Initiating Cells: Relationship with Neural Stem Cells and the Micro-Environment

4. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

5. Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population-based analysis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Validation of a Targeted Treatment for Brain Tumors Using a Multi-Drug Loaded, Relapse-Resistant Polymeric Theranostic;Biomacromolecules;2023-05-05

2. Efficient delivery of Temozolomide using ultrasmall large-pore silica nanoparticles for glioblastoma;Journal of Controlled Release;2023-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3